Takeda Pharmaceutical Company Limited (TSE:4502) today announced the initiation of an international phase 3 clinical trial evaluating once a week MLN9708 in combination with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma who are not candidates for transplant. The multi-center study with MLN9708, an investigational, oral proteasome inhibitor, will be conducted in Europe and North America.
“The TOURMALINE-MM2 study is the first all oral triplet combination regimen including both a proteasome inhibitor and an IMiD to be investigated in newly diagnosed myeloma patients.”
"The initiation of this front line myeloma trial represents another first in the development of MLN9708, an oral proteasome inhibitor, and is a major achievement in advancing the Takeda Oncology pipeline," said Karen Ferrante, M.D, Head of the Takeda Oncology Therapeutic Unit. "The TOURMALINE-MM2 study is the first all oral triplet combination regimen including both a proteasome inhibitor and an IMiD to be investigated in newly diagnosed myeloma patients."
Innovative CAR T cell therapy targets two proteins to combat aggressive brain tumor growth